Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study
17 mai 2021 08h42 HE
|
Skye Bioscience, Inc.
THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours,...
Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program
22 avr. 2021 08h30 HE
|
Skye Bioscience, Inc.
Novel glaucoma drug ready for next development phase - GLP toxicology study – on critical path to first human clinical trialOngoing development of THCVHS includes near-term preclinical comparison with...
Skye Bioscience to Present at Upcoming Investment Conferences in April
15 avr. 2021 08h45 HE
|
Skye Bioscience, Inc.
San Diego, Calif, April 15, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience to Present at Benzinga Biotech Small Cap Conference
18 mars 2021 08h45 HE
|
Skye Bioscience, Inc.
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
16 mars 2021 08h30 HE
|
Skye Bioscience, Inc.
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board
08 mars 2021 08h39 HE
|
Skye Bioscience, Inc.
San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference
03 mars 2021 08h37 HE
|
Skye Bioscience, Inc.
San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Skye Bioscience to Participate in Investment Conferences in February
03 févr. 2021 09h09 HE
|
Skye Bioscience, Inc.
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
19 janv. 2021 08h30 HE
|
Skye Bioscience, Inc.
San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th
15 janv. 2021 13h30 HE
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary,...